"Good vibes Here Dudes"....., page-79

The usual spiel now I see. Diversion to the beginning for the next lap of honour.

Green highlighting:

"May 26, 2022" - I checked, there was a May in 2022. CHECKED

"hugely important" - IND in the US with the potential to start other trials by piggy-backing on the FDA provided CMC data is very important. The data will also add to the initial SR-aGvHD treatment and may even show a benefit as a first-line treatment before SR onset, setting it apart from the likes of Ryoncil who is trying to obtain approval in SR-aGvHD in children, with the possibility of an adult label extension. CHECKED

"delighted... to commence a US trial" - see above. CHECKED

Reading between the lines, why is it not being celebrated that another patient in the US was diagnosed with aGvHD and is at a situation where it will very likely lead to SR and subsequently a survival chance of less than 50%? Yeah, I leave that up to you to find out.

Yellow highlighting:

"it's first... in the US" - can confirm, all others were preclinical studies. CHECKED.

Statement:

KK GvHD or OA - GvHD in P2 (recruitment commenced) and OA (P3 last patient dosed months ago), yes, that makes sense that these are the indications closest to commercialise. Nothing to see here.
Ross (and FF) said GvHD by 2024 - correct. Didn't happen. A missed deadline that no one else seems to have noticed. Oh wait, discussed many times before. Nothing to see here either.

OA 01/04/28 in AU,
GvHD 01/04/30 after a P3 trial.

More good vibes, dude.